Prognosis
J&J’s One-Shot Covid Vaccine Receives FDA Advisers’ Backing
- Presentations show low rate of side effects, rising immunity
- Clearance could come soon after panel’s vote to recommend
This article is for subscribers only.
Johnson & Johnson’s single-shot coronavirus vaccine won the backing of a panel of U.S. government advisers, paving the way for authorization of the country’s third immunization against the deadly virus.
Experts advising the U.S. Food and Drug Administration voted 22-0, with no abstentions, that the benefits of the vaccine outweigh its risks in adults 18 and older, a decision that could help bolster the vaccine supply as new variants continue to spread. The FDA usually follows the nonbinding recommendations of its advisory panels and could authorize the shot within days.